Pay in 4 interest-free payments of $5.35 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
All results were statistically significant except the heart failure finding
The robust weight loss combined with a well-tolerated safety profile reinforces our confidence in the clinical development programme [of CT-388] as we advance to phase III trials" Dr Levi Garraway, PhD, Roches Chief Medical Officer and Head of Global Product Development, said: We are pleased to see such meaningful weight loss in people treated with CT-388
Semaglutide has a longer track record and more published long-term safety data, which some patients and providers find reassuring
Its smart to avoid hard workouts immediately after eating because these tend to amplify nausea
Some patients use semaglutide for defined periods to achieve target weights, then taper or discontinue
